Navigation Links
Iomai Reports 'Going Concern' Qualification in 10-K
Date:3/28/2008

GAITHERSBURG, Md., March 28 /PRNewswire-FirstCall/ -- Iomai Corporation (Nasdaq: IOMI) today announced, in compliance with NASDAQ marketplace rules, that the independent audit report included in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 27, 2008 for the fiscal year ended December 31, 2007 contained a "going concern" qualification. This disclosure is required under NASDAQ marketplace rules and does not represent any change to the Company's Annual Report on Form 10-K for the year ended December 31, 2007 and filed on March 27, 2008 with the SEC.

ABOUT IOMAI CORPORATION

Iomai Corporation discovers and develops vaccines and immune system stimulants, delivered via a novel, needle-free technology called transcutaneous immunization (TCI). TCI, discovered by researchers at the Walter Reed Army Institute of Research, taps into the unique benefits of a major group of antigen-presenting cells found in the outer layers of the skin (Langerhans cells) to generate an enhanced immune response. Iomai is leveraging TCI to enhance the efficacy of existing vaccines, develop new vaccines that are viable only through transcutaneous administration and expand the global vaccine market. Iomai currently has four product candidates in development: three targeting influenza and pandemic flu and one to prevent travelers' diarrhea. For more information on Iomai, please visit http://www.iomai.com.


'/>"/>
SOURCE Iomai Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Study Finds Single Dose of Iomai Patch With Pandemic Flu Vaccine Achieves Protective Levels
2. Iomai CEO to Speak at Cowen and Company Health Care Conference on Monday, March 17
3. Iomai Study Shows Self-Applied Travelers Diarrhea Vaccine Patch Comparable to Clinician-Applied Vaccine Patch
4. Iomai Patch-Based Vaccine Cut Rate of Travelers Diarrhea by 75 Percent in Phase 2 Field Study
5. Hospital for Special Surgery Reports Scores on HCAHPS Survey
6. PreMD Reports Fiscal 2007 Results
7. Interleukin Genetics Reports Fourth Quarter and Year End 2007 Financial Results
8. CryoCor Reports Going Concern Statement and Receives Notification From Nasdaq Relating to Minimum Stockholders Equity
9. Spheris Reports Fourth Quarter and Year-End 2007 Results
10. NeurogesX Reports Fourth Quarter and Year-End 2007 Financial Results
11. QMed, Inc. Reports Year-End and Fourth Quarter Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... , ... “The Journey: From the Mountains to the Mission Field”: the story ... the Philippines. “The Journey: From the Mountains to the Mission Field” is the creation ... has taught all ages and currently teaches a class of ladies at her church, ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San Francisco ... using cutting-edge Oventus O2Vent technology. As many as 18 million Americans are estimated ... in breathing. Oral appliances can offer significant relief to about 75 percent of ...
(Date:10/12/2017)... ... ... IsoComforter, Inc. ( https://isocomforter.com ), one of the Nation’s premier ... of the shoulder pad. The shoulder pad provides optimal support and full contact ... using cold therapy. By utilizing ice and water that is circulated from an insulated ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information ... we intend to develop to enable prevention of a major side effect of ... loss, especially in pediatric patients. For cisplatin, hearing loss is FDA listed on-label ...
(Date:10/12/2017)... ... October 12, 2017 , ... Leading pediatric oncology experts ... Washington, D.C., for the 49th Congress of the International Society of Paediatric Oncology ... of the Center for Cancer and Blood Disorders at Children’s National, and ...
Breaking Medicine News(10 mins):
(Date:10/4/2017)... 4, 2017  South Korean-based healthcare product Development Company ... "cprCUBE" on Kickstarter. The device will educate the user ... with better efficiency compared to the dated and pricey ... on efficacy of the compression for a more informed ... goal to raise $5,000. ...
(Date:10/2/2017)... 2, 2017 Diplomat Pharmacy, Inc. (NYSE: ... and Consulting, LLC , and named its founder as ... in Tennessee , will operate under ... EnvoyHealth,s service offerings for health care partners to include ... "In an interoperable world, technology delivers ...
(Date:10/2/2017)... Halo Labs announces the European launch of their new ... at MIBio 2017 in Cambridge, U.K on ... in biopharmaceutical samples with unprecedented speed and sensitivity while using far ... Membrane Imaging. ... particle analysis system ...
Breaking Medicine Technology: